

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618

Technical Data Sheet

PE conjugated Human Vista (C-Fc)

Catalog Number: 814201, 814202

Size: 25 ug, 100 ug

Target Name: B7-H5, SISP1, Gi24, VISTA

Regulatory Status: RUO

Product Details

Application: FC
Format: Liquid, PE
Expression Host: CHO

Species: Human

Sources: Recombinant Human Vista (Phe33-Ala194) with C-terminus Fc-tag is expressed in CHO

cell and conjugated to PE.

Accession Number: Q9H7M9

Molecular Weight: The protein has a predicted molecular weight of 45 kDa. Under DTT-reducing

conditions, it migrates at approximately 55-65 kDa on SDS-PAGE prior to conjugation.

Affinity Tag: C-Fc

Formulation: 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein

Endotoxin level: Not tested

Protein Concentration: 25μg size is bottled at 0.1mg/mL concentration. 100 μg size is bottled at lot

specific concentration.

Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial may be stored at

2-8°C for up to six months.

Background Information

VISTA (V-domain Ig suppressor of T cell activation), also known as VSIR, PD-1H, or C10orf54, is a type I transmembrane protein with a single IgV-like extracellular domain and functions as an inhibitory immune checkpoint molecule. It is broadly expressed on myeloid cells, T cells, dendritic cells, and in tissues such as spleen and bone marrow. VISTA suppresses CD4+ and CD8+ T cell activation and cytokine production, contributing to immune tolerance and regulation. It may also play a role in embryonic stem cell differentiation by modulating BMP4 signaling. VISTA undergoes proteolytic cleavage, generating both soluble and membrane-bound fragments, and its interaction with PSGL1 in low-pH tumor microenvironments has been reported. Due to its immunosuppressive properties, VISTA is considered a promising target for cancer immunotherapy and may be involved in inflammatory conditions such as chronic rhinosinusitis with nasal polyps.